Skip to main content

Leukemia, Acute Myeloid

Jan Cerny, PhD, MD Reviewed 06/2022
 


BASICS

DESCRIPTION

  • Acute myeloid leukemia (AML) is characterized by proliferation of abnormal immature myeloid progenitors (blasts) with reduced capacity to differentiate leading to bone marrow failure...

DIAGNOSIS

HISTORY

Fatigue (anemia or tumor burden); bleeding (low platelets or DIC); difficulty clearing infections (neutropenia or immune dysregulation) 

PHYSICAL EXAM

  • Mostly nonspecific and related to ...

TREATMENT

  • Classical (cytotoxic) chemotherapy has been the backbone of AML therapy; it consists of induction and consolidation phase ± maintenance (APL), but more recently other transplant ineligible A...

ONGOING CARE

FOLLOW-UP RECOMMENDATIONS

Patient Monitoring

  • Repeat bone marrow studies to document remission and also if a relapse is suspected.

  • Follow CBC with differential, coagulation studies, uric acid...

REFERENCES

1
Döhner  H, Estey  EH, Amadori  S, et al; for European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an internation...

ADDITIONAL READING

O’Donnell  MR, Appelbaum  FR, Coutre  SE, et al. Acute myeloid leukemia. J Natl Compr Canc Netw.  2008;6(10):962–993. [View Abstract on OvidMedline] ...

SEE ALSO

Disseminated Intravascular Coagulation; Leukemia, Acute Lymphoblastic (ALL) in Adults; Leukemia, Chronic Myelogenous; Myelodysplastic Syndromes (MDS); Myeloproliferative Neoplasms 

CODES

ICD10

  • C92.00 Acute myeloblastic leukemia, not having achieved remission

  • C92.01 Acute myeloblastic leukemia, in remission

  • C92.02 Acute myeloblastic leukemia, in relapse

SNOMED

  • 91861009 Acute myeloid l...

CLINICAL PEARLS

  • Acute myeloid leukemia (AML) is a proliferation and accumulation of abnormal immature myeloid progenitors (blasts) with reduced capacity to differentiate into more mature cellular elem...

Subscribe to Access Full Content

Sign Up for a 10-Day Free Trial

Sign up for a 10-day FREE Trial now and receive full access to all content.

 
×